U.S. FDA Issues Warning For Contamination At Cadila's India Site
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - U.S. FDA has issued a warning letter to India's Cadila Healthcare Ltd. citing significant violations of current good manufacturing practices at its Sarkhej plant, near the Western city of Ahmedabad. The facility was inspected between Jan.17 and Feb. 3